Abivax (ABVX) Receivables - Other (2023 - 2026)

Abivax's Receivables - Other history runs 4 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 28.95% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 28.95% decrease from a year earlier, with the FY2025 full-year figure at $15.3 million, down 25.19% from the prior year.
• Receivables - Other advanced to $16.1 million in Q1 2026 per ABVX's latest filing, from $15.3 million in the prior quarter.
• Across five years, Receivables - Other topped out at $26.7 million in Q4 2023 and bottomed at $15.3 million in Q4 2025.
• The 4-year median for Receivables - Other is $21.2 million (2024), against an average of $20.8 million.
• Across the five-year window, Receivables - Other retreated 12.26% in 2025 and declined 28.95% in 2026, its largest moves.
• Year by year, Receivables - Other stood at $26.7 million in 2023, then decreased by 24.46% to $20.2 million in 2024, then declined by 24.23% to $15.3 million in 2025, then rose by 5.34% to $16.1 million in 2026.
• Per Business Quant, the three latest ABVX Receivables - Other figures stand at $16.1 million (Q1 2026), $15.3 million (Q4 2025), and $23.9 million (Q3 2025).